Showing 1761-1770 of 3223 results for "".
- Alcon Receives Health Canada Approval for Unity VCShttps://modernod.com/news/alcons-receives-health-canada-approval-for-unity-vcs/2482882/Alcon announced that Unity Vitreoretinal Cataract System (VCS) has received Health Canada approval. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon’s current leading systems, Constellation Vision System for vitreoretinal and combined proce
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMDhttps://modernod.com/news/alcon-to-acquire-lumithera-maker-of-photobiomodulation-device-for-the-treatment-of-dry-amd/2482873/In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD.
- Alcon Introduces Clareon PanOptix Pro in Canadahttps://modernod.com/news/alcon-introduces-clareon-panoptix-pro-in-canada/2482857/Alcon announced the approval of Clareon PanOptix Pro IOL in Canada. According to Alcon, PanOptix Pro leverages the company's proprietary 'ENLIGHTEN NXT' optical technology, which delivers the lowest light scatter and highest reported light utilization of
- Aldeyra Resubmits Reproxalap NDA for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-resubmits-reproxalap-nda-for-the-treatment-of-dry-eye-disease/2482851/Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. Per FDA agreement
- Alcon Receives FDA Approval of Tryptyr for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/alcon-receives-fda-approval-of-tryptyr-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2482823/Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of dry eye disease (DED). Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal senso
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- Aldeyra Plans to Resubmit NDA for DED Candidate Reproxalap After Dry Eye Chamber Trial Resultshttps://modernod.com/news/aldeyra-plans-to-resubmit-nda-for-ded-candidate-reproxilap-after-dry-eye-chamber-trial-results/2482788/Aldeyra Therapeutics announced it has achieved the primary endpoint in a phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of its investigational drug candidate reproxalap.
- Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo Uveohttps://modernod.com/news/iantrek-hits-2000-procedures-for-new-bio-interventional-technology-alloflo-uveo/2482785/Iantrek announced it has surpassed 2,000 AlloFlo Uveo procedures in the US. The key milestone comes ahead of its full commercial launch planned for this fall during the American Academy of Ophthalmology 2025 meeting. Recent momentum has been fueled by the publication of 2-year
- Alcon Offers Eye Care Innovators a Shot at $1M Seed Investmenthttps://modernod.com/news/alcon-offers-eye-care-innovators-a-shot-at-1m-seed-investment/2482779/Alcon announced a collaboration with the Association for Research in Vision and Ophthalmology (ARVO) to support its live